Immune privileged and modulatory progenitor cells
OwnerJohn E. Davies, Jane Ennis +2inventors
InventorsJohn E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh
Life of this patent
Estimating the term…
Abstract
Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
Claims14
A method for treating a subject having or at risk of developing an adverse immune reaction, comprising administering to the subject an immunomodulating effective amount of an agent selected from umbilical cord perivascular cells, wherein said adverse immune reaction is directed against biological material other than said agent and wherein said administering treats said subject by inhibiting or reducing said adverse immune reaction.
Dependencies are inferred from the claim text.